Before the COVID-19 pandemic, Mycoplasma pneumoniae infections emerged during spring to summer yearly in Taiwan, but infections were few during the pandemic. M. pneumoniae macrolide resistance soared to 85.7% in 2020 but declined to 0% during 2022-2023. Continued molecular surveillance is necessary to monitor trends in macrolide-resistant M. pneumoniae.
Keywords: COVID-19; Mycoplasma pneumoniae; SARS; SARS-CoV-2; Taiwan; antimicrobial resistance; bacteria; coronavirus; coronavirus disease; macrolide resistance; molecular epidemiology; multilocus sequence typing; pneumonia; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.